Top Stock Market Movers Rise Over 200% As Intel and Biotech Surge

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  18 Sep 2025
 

•   ABAT  
   
  +5.63%
•   AERT  
   
  +5.68%
•   APVO  
   
  +3.13%
•   AQB  
   
  +2.80%
•   BREA  
   
  -31.39%

$BREA delivered the most spectacular performance with a staggering 225.49% surge to $24.90, driven by Wall Street's overwhelming enthusiasm for the company's groundbreaking $300 million private placement announcement. Brera Holdings PLC captured investor attention by revealing plans to establish a Solana digital asset treasury, backed by heavyweight supporters including Ark Invest and UAE investors. The oversubscribed nature of this funding round signals strong institutional confidence in the company's blockchain strategy, positioning BREA as a potential bridge between traditional finance and the rapidly evolving digital asset ecosystem.

$ETNB rocketed 85.15% to $14.96 following Roche's blockbuster $3.5 billion acquisition offer for 89bio, the MASH drug developer. Shareholders stand to receive up to $20.50 per share in cash, comprising $14.50 at closing plus a contingent value right worth up to $6.00 per share. This represents a premium of approximately 79% to the previous day's closing price, reflecting Roche's aggressive push into obesity-tied diseases and cardiometabolic treatments. The deal underscores the pharmaceutical giant's commitment to expanding its pipeline in high-growth therapeutic areas, particularly as MASH represents a significant unmet medical need with substantial market potential.

$AERT climbed 63.85% to $0.93 after announcing a multi-million dollar partnership expected to generate up to $8 million in annual contract value. Aeries Technology's agreement with a global marketing and technology company focuses on expanding AI capabilities and establishing an India footprint for the client. This milestone contract demonstrates the company's ability to capitalize on the growing demand for AI-enabled business transformation services, particularly among private equity portfolio companies seeking to scale their operations efficiently.

$APVO surged 40.43% to $1.98 during after-hours trading following breakthrough clinical results in its Phase 1b/2 RAINIER trial for AML treatment. Aptevo Therapeutics reported that all patients in Cohort 3 achieved complete remission with no dose-limiting toxicities or cytokine release syndrome across all trial cohorts. These remarkable results position the Seattle-based biotech company's drug as a potential game-changer in frontline AML treatment, offering hope for patients facing this aggressive form of leukemia.

$AQB exploded 98.25% in after-hours trading to $2.26 after meeting NASDAQ's minimum bid price requirement, effectively removing the delisting threat that had been weighing on the stock. AquaBounty Technologies' compliance with exchange listing standards provided immediate relief to investors who had been concerned about the biotech company future trading status, triggering a massive short covering rally.

$ABAT gained 23.46% to $3.00 as American Battery Technology Company reported fiscal 2025 fourth quarter results showing nearly triple quarterly revenue growth. The company achieved more than 180% increase in quarterly revenue while accelerating commercial operations to boost onshoring of critical mineral manufacturing, positioning itself strategically in the domestic battery supply chain ecosystem.

$INTC soared 22.77% to $30.57 on news of Nvidia's historic $5 billion investment and strategic partnership announcement. The collaboration involves co-developing custom data center CPUs and x86 RTX SOCs for PCs, combining Nvidia's AI expertise with Intel's CPU strengths. This landmark deal represents a lifeline for the struggling chipmaker, thrusting Intel back into the center of the artificial intelligence revolution after years of competitive challenges. The partnership, coupled with recent government backing, signals a potential turnaround for one of Silicon Valley's most iconic companies.

Bottom line - $INTC offers the most attractive near-term opportunity given Nvidia's substantial $5 billion commitment, the strategic nature of their chip development partnership, and Intel's deeply discounted valuation following years of underperformance. The combination of financial backing and technological collaboration with the AI leader creates a compelling catalyst for sustained recovery.

View All Headlines